Valuation: Mymetics Corp

Market Cap 439K 381K 355K 326K 616K 41.89M 625K 4.18M 1.64M 20.85M 1.65M 1.61M 69.92M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.7M 58.36M 53.58M 101M 6.88B 103M 688M 270M 3.43B 271M 265M 11.49B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-11.43%+44.21% - - 45
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -1.26%-3.79%+35.87%+154.81% 25.98B
Weighted average by Cap. +0.23%-2.96%+30.79%+116.84%

Financials

2021 2022
Net sales 430K 374K 348K 319K 603K 41.05M 613K 4.1M 1.61M 20.44M 1.61M 1.58M 68.52M 1.03M 894K 832K 764K 1.44M 98.13M 1.46M 9.8M 3.85M 48.86M 3.86M 3.78M 164M
Net income -4.73M -4.11M -3.83M -3.51M -6.64M -452M -6.74M -45.11M -17.71M -225M -17.76M -17.37M -754M -4.8M -4.18M -3.89M -3.57M -6.74M -459M -6.85M -45.83M -17.99M -228M -18.05M -17.65M -766M
Net Debt 67.1M 58.33M 54.29M 49.85M 94.13M 6.41B 95.59M 640M 251M 3.19B 252M 246M 10.69B 71.68M 62.31M 58M 53.25M 101M 6.84B 102M 684M 268M 3.41B 269M 263M 11.42B
Logo Mymetics Corp
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-